Loading...
Loading...
MOLN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 9,449.0K |
| Gross Profit | -9,449.0K |
| Operating Expense | 5,345.0K |
| Operating I/L | -14,794.0K |
| Other Income/Expense | 3,564.0K |
| Interest Income | 651.0K |
| Pretax | -11,230.0K |
| Income Tax Expense | 2.0K |
| Net Income/Loss | -11,232.0K |
Molecular Partners AG is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic proteins. The company's product candidates include Abicipar for the treatment of neovascular wet age-related macular degeneration and diabetic macular edema, as well as MP0420 for the SARS-CoV-2 virus. Additionally, it develops products for immuno-oncology, tumor-localized immune agonists, and HER2-positive cancers. Molecular Partners AG has collaborations with Novartis AG, Amgen SA, Allergan, Inc., and AbbVie Inc. The company generates revenue through the development, manufacturing, and commercialization of its DARPin-conjugated radioligand therapies and other therapeutic protein products.
